NKTR 214

Drug Profile

NKTR 214

Alternative Names: NKTR-214

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator Nektar Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Developer Bristol-Myers Squibb; Nektar Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cytokines
  • Mechanism of Action Immunostimulants; Interleukin-2 receptor beta subunit agonists; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Bladder cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 04 Apr 2017 Pharmacodynamics data from a preclinical trial in Cancer reported at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 20 Mar 2017 Nectar Therapeutics plans the phase I/II PROPEL trial for Non-small cell lung cancer and urothelial carcinoma (Combination therapy, Second-line therapy or greater) in mid-2017 (Nectar Therapeutics website, March 2017)
  • 18 Feb 2017 Efficacy and immunogenicity data from a phase I trial in Solid tumours (Metastatic disease, Second-line therapy or greater) released by Nektar Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top